[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pediatric-sepsis-induced-multiple-organ-dysfunction-syndrome-mods\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pediatric-sepsis-induced-multiple-organ-dysfunction-syndrome-mods":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100459838",false,"NCT05267821","Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS","Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS (TRIPS)","TRIPS","Inclusion Criteria:\n\n* ≥ 40 weeks corrected gestational age to \\\u003C 18 years; AND\n* Admission to the PICU or CICU; AND\n* Onset of ≥ 2 new organ dysfunctions within the last 3 calendar days (compared to pre-sepsis baseline) as measured by the modified Proulx criteria; AND\n* Documented or suspected infection as the MODS inciting event.\n\nExclusion Criteria:\n\n* Weight \\\u003C3kg; OR\n* Limitation of care order at the time of screening; OR\n* Patients at high likelihood of progression to brain death in opinion of the clinical team; OR\n* Moribund condition in which the patient is unlikely to survive the next 48 hours in opinion of the clinical team; OR\n* Current or prior diagnosis of hemophagocytic lymphohistiocytosis or macrophage activation syndrome; OR\n* Peripheral white blood cell count \\\u003C 1,000 cells\u002Fmm3 as the result of myeloablative therapy OR receipt of myeloablative therapy within the previous 14 days; OR\n* Known allergy to anakinra, or E. coli-derived products; OR\n* Known pregnancy; OR\n* Lactating females; OR\n* Receipt of anakinra within the previous 28 days; OR\n* Resolution of MODS by MODS Day 2; OR\n* Previous enrollment in the TRIPS study.","ALL","1 Day","17 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).",[28],"Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)","RECRUITING","2026-03-11",{"date":32,"type":33},"2026-03-13","ACTUAL",{"date":35,"type":33},"2022-06-14",{"date":37,"type":21},"2028-08-31",{"name":39,"class":40},"Nationwide Children's Hospital","OTHER",32,""]